Company Description

Valion Bio, Inc. operates as a late-stage biopharmaceutical company.

Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.

The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence.

In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026.

The company was incorporated in 2016 and is based in San Antonio, Texas.

Valion Bio, Inc.

Country	United States
Founded	2016
IPO Date	Nov 11, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	52
CEO	Michael Handley

Contact Details

Address: 1305 E. Houston Street, Suite 311, Building 1 San Antonio, Texas 78205 United States
Phone	888 276 6888
Website	tivichealth.com

Stock Details

Ticker Symbol	VBIO
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1787740
Employer ID	81-4016391
SIC Code	3845

Key Executives

Name	Position
Michael Kevin Handley	Chief Executive Officer and Director
Lisa G. Wolf	Chief Financial Officer and Principal Financial and Principal Accounting Officer
Melinda Lackey	General Counsel and Senior Vice President of Legal Affairs

Latest SEC Filings

Date	Type	Title
May 14, 2026	10-Q	Quarterly Report
May 14, 2026	8-K	Current Report
May 8, 2026	SCHEDULE 13G/A	Filing
May 4, 2026	8-K	Current Report
Apr 30, 2026	ARS	Filing
Apr 30, 2026	DEF 14A	Other definitive proxy statements
Apr 23, 2026	8-K	Current Report
Apr 20, 2026	PRE 14A	Other preliminary proxy statements
Apr 15, 2026	EFFECT	Notice of Effectiveness
Apr 15, 2026	424B3	Prospectus

View All SEC Filings